Ofloxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbation of chronic bronchitis

Pérez-Gonzalvo, Máximo E.; Mosquera-Pestaña, JoséA.; Ramos, David; Apilánez, Javier; Borja, Javier; Arnau, C.; García-Barbal, J; Julio-Marín-Pardo,

doi:10.1016/s0149-2918(96)80024-5

Search citation statements

Order By: Relevance

Paper Sections

Select...

Chronic Bronchitis (Acute Exacerbations)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1998

2006

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ofloxacin has also been shown to be effective [12–14]. Chodosh reviewed the use of enoxacin, ciprofloxacin, ofloxacin and temafloxacin in acute exacerbations of chronic bronchitis, and the last three were generally more effective than enoxacin [15].…”

Section: Chronic Bronchitis (Acute Exacerbations)mentioning

confidence: 99%

Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones

Rubinstein

Carbon

Rangaraj³

et al. 1998

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Section: Chronic Bronchitis (Acute Exacerbations)mentioning

confidence: 99%

Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones

Rubinstein

Carbon

Rangaraj³

et al. 1998

Clinical Microbiology and Infection

View full text Add to dashboard Cite

Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis

Léophonte

Baldwin²,

Pluck

1998

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

Treatments with once-daily trovafloxacin (200 or 100 mg) and amoxicillin/clavulanic acid (500/125 mg three times daily) were compared in adults with acute exacerbations of chronic obstructive bronchitis. At end of treatment, 95% (113/119) of clinically evaluable patients receiving trovafloxacin 200 mg, 98% (113/115) of patients treated with trovafloxacin 100 mg and 97% (113/117) of patients receiving amoxicillin/clavulanic acid were cured or improved. At study end, 91%, 87% and 88%, respectively, were cured or improved. At end of treatment, trovafloxacin 200 mg eradicated Haemophilus influenzae in 97% of patients, Streptococcus pneumoniae in 90% and Chlamydia pneumoniae in 100%. The respective eradication rates for trovafloxacin 100 mg were 84%, 100% and 100%; those for amoxicillin/clavulanic acid were 92%, 100% and 100%. At study end, trovafloxacin 200 mg totally eradicated all three pathogens. Trovafloxacin 100 mg eradicated Haemophilus influenzae in 91% of patients, Streptococcus pneumoniae in 100% and Chlamydia pneumoniae in 80%. Respective eradication rates for amoxicillin/clavulanic acid were 78%, 100% and 80%. Only 7% (10/144) of patients receiving trovafloxacin 200 mg reported treatment-related adverse events, as did 7% (10/135) of patients given trovafloxacin 100 mg and 12% (17/140) of patients given amoxicillin/clavulanic acid.

show abstract

Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis

Perfetto

Mullins²,

Subedi

et al. 2001

Clinical Therapeutics

View full text Add to dashboard Cite

Ofloxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with acute exacerbation of chronic bronchitis

Cited by 6 publications

References 9 publications

Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones

Lower respiratory tract infections: etiology, current treatment, and experience with fluoroquinolones

Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis

Selection of clinical, patient-reported, and economic end points in acute exacerbation of chronic bronchitis

Contact Info

Product

Resources

About